Leyden Laboratories

Leyden Laboratories is striving to liberate people from the threat of respiratory viruses. Leyden Laboratories is leveraging its mucosal protection platform to develop a series of drug candidates, aiming to provide protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays. CR9114, the leading candidate in Leyden Laboratories' PanFlu program, is a human monoclonal antibody that has demonstrated prevention of influenza in preclinical models.